Teacher Retirement System of Texas Sells 2,196 Shares of Insulet Co. (NASDAQ:PODD)

Teacher Retirement System of Texas cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 40.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,203 shares of the medical instruments supplier’s stock after selling 2,196 shares during the period. Teacher Retirement System of Texas’ holdings in Insulet were worth $695,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Orion Portfolio Solutions LLC lifted its position in Insulet by 9.3% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 2,714 shares of the medical instruments supplier’s stock valued at $433,000 after acquiring an additional 231 shares in the last quarter. Signaturefd LLC boosted its position in shares of Insulet by 120.5% during the third quarter. Signaturefd LLC now owns 732 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 400 shares during the period. Ieq Capital LLC grew its holdings in shares of Insulet by 249.9% during the third quarter. Ieq Capital LLC now owns 5,388 shares of the medical instruments supplier’s stock worth $859,000 after buying an additional 3,848 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Insulet by 663.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 36,228 shares of the medical instruments supplier’s stock valued at $5,778,000 after buying an additional 31,483 shares during the last quarter. Finally, HM Payson & Co. bought a new stake in Insulet in the 3rd quarter valued at approximately $48,000.

Insider Activity at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.47% of the stock is owned by company insiders.

Insulet Stock Up 5.4 %

Shares of PODD opened at $180.07 on Friday. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $298.95. The firm has a market cap of $12.61 billion, a P/E ratio of 54.57, a price-to-earnings-growth ratio of 3.07 and a beta of 1.00. The firm’s 50-day simple moving average is $171.74 and its 200 day simple moving average is $184.36. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The business had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. During the same quarter in the prior year, the business earned $0.23 EPS. Insulet’s quarterly revenue was up 23.3% on a year-over-year basis. On average, analysts forecast that Insulet Co. will post 3.11 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on PODD shares. Stifel Nicolaus lifted their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Piper Sandler cut their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Raymond James lowered their target price on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Jefferies Financial Group increased their price target on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Finally, Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research report on Tuesday, May 7th. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $239.44.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.